A prospective cohort study with annual follow-up was conducted on 172 children with spastic type cerebral palsy receiving botulinum toxin type A (BTX) injections for spasticity management. A mixed modeling procedure was used to identify changes in both physical functioning outcomes for the child (using the WeeFIM measure) as well as quality of life of the parent caregiver (using the Stein and Reissman Impact on the Family Scale) with increasing utilization of BTX injections. The study found that each additional BTX injection administration was associated with a 2.3% improvement in the WeeFIM compared to the average baseline score (p < .01). Similarly, the study found an improvement of 2.5% compared to baseline in the parent's overall perception of the severity of the child's condition with each additional BTX injection administration (p < .001). These findings suggest that BTX injections may be associated with beneficial outcomes in childhood spasticity.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Iatrogenic Botulism After Cosmetic Use of Botulinum Toxin-A: A Case Series.
Clin Case Rep
January 2025
Toxicological Research Center, Excellence Center & Department of Clinical Toxicology, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.
Botulism symptoms after cosmetic botulinum toxin-A (BTX-A) injections happen very rarely, and it needs careful attention since it can be life-threatening. Hence, it is advised to meticulously check the technique, dose, and authenticity of the BTX-A before injections to reduce the adverse effects.
View Article and Find Full Text PDFIntradermal Incobotulinum Toxin A for Postbreast Cancer Treatment Asymmetry: A Literature Review and Case Report.
J Cosmet Dermatol
January 2025
Ophthalmologist - Oculoplastic Surgery, Sociedad Internacional de Rejuvenecimiento Facial no Quirurgico (SIRF), Barranquilla, Colombia.
Background: Botulinum toxin (BTX) is globally the most common aesthetic procedure. Its usage has expanded beyond facial treatments to therapeutic areas, including managing scars and postsurgical deformities. Breast cancer survivors often face significant deformities and asymmetry during recovery.
View Article and Find Full Text PDFContemporary Algorithm for Treating Bromhidrosis: A Review of Treatment Available.
Aesthetic Plast Surg
January 2025
Department of Plastic Surgery, The First Affiliated Hospital of Fujian Medical University, No. 20, Chazhong Road, Taijiang District, Fuzhou, China.
Bromhidrosis significantly impacts individuals' social, professional, and emotional well-being. Traditional treatments such as en bloc excision and alcohol injections are now less favored due to associated complications and suboptimal outcomes. Current evidence identifies botulinum toxin A (BTX-A) as the first-line treatment for mild to moderate cases (Grade 0-2), attributed to its high efficacy, excellent safety profile, and minimally invasive nature.
View Article and Find Full Text PDFEarly effects of α7nAChR regulation on maxillary expansion in mice : A study on osteogenesis and inflammatory factors.
J Orofac Orthop
December 2024
Department of Orthodontics, Beijing Stomatological Hospital, Capital Medical University, 100050, Beijing, China.
Purpose: We aimed to investigate early effects of regulating alpha‑7 nicotinic acetylcholine receptor (α7nAChR) agonists and antagonists on maxillary expansion in mice.
Methods: We allocated 36 six-week-old male C57BL/6J mice into three group: 1) expansion alone, 2) expansion plus the α7nAChR-specific agonist 3‑(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride (GTS-21), and 3) expansion plus alpha-bungarotoxin (α-BTX), a competitive antagonist of α7nAChR. The groups were daily injected with saline, GTS-21 (4 mg/kg/day) or α‑BTX (1 mg/kg/day), respectively, from days 0-7.
Tolerability and efficacy of botulinum toxin injection in the treatment of bromhidrosis: a systematic review and meta-analysis of clinical trials.
Acta Dermatovenerol Alp Pannonica Adriat
December 2024
College of Medicine, Sulaiman Al Rajhi University, Bukaryiah, Saudi Arabia.
This review evaluates the risks and benefits of botulinum toxin (BTX) therapy for treating bromhidrosis. A search was conducted across six databases, including clinical trials comparing BTX therapy with BTX-free controls. The analyzed outcomes included pooled adverse events (AEs), treatment success, ≥ 50% overall improvement, and recurrence rates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!